Sector News

Forma’s John Hohneker takes the reins at Anokion

January 18, 2018
Life sciences

After shepherding Forma Therapeutics from its discovery stage to clinical trials as its R&D chief, John Hohneker is joining Anokion Therapeutics as president and CEO, effective Jan. 22.

“John brings tremendous experience in biologics development to Anokion, including in the immunology space. His broad leadership in both preclinical and clinical development will strengthen Anokion’s powerful platforms in immunological tolerance,” said Jeffrey Hubbell, the academic founder, chairman and chief scientific officer of Anokion, in a statement.

Anokion, a spinout of the Ecole Polytechnique Fédérale de Lausanne in Switzerland, is working on an antigen-specific immune tolerance platform for the development of new treatments for autoimmune disease.

The tech is designed for “diverse applications,” the company says, including tolerizing the immune system to self-antigens behind autoimmune diseases, as well as cutting the immunogenicity of therapeutic proteins.

The biotech is advancing two approaches to exploit the body’s natural tolerance mechanism of apoptotic, or aging, cells. Both involve engineering antigens to provoke a tolerogenic immune response—in the first, the antigens bind to a surface protein unique to red blood cells, while in the second, they bind to liver cells.

In addition to his R&D experience at Forma, Hohneker served in a number of roles at Novartis, most recently as senior vice president and global head of development for immunology and dermatology.

In January last year, Celgene plunked down $45 million up front to join forces with Anokion on tolerance-inducing treatments. Anokion stands to collect another $10 million if it hits certain preclinical performance marks, while Celgene picked up an equity interest in Anokion and the exclusive right to acquire the biotech at a later date.

By Amirah Al Idrus

Source: Fierce Biotech

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).